Jonathan J Lewis, MD, PhD
ZIOPHARM, Oncology, Inc. · ZIOPHARM Oncology, Inc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jonathan J Lewis, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:11 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01139359 · Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat LymphomaAlaunos Therapeutics · withdrawn · Lymphoma · study director
- Ph1NCT01139346 · Study of Oral Darinaparsin in Patients With Advanced Solid TumorsAlaunos Therapeutics · completed · Advanced Solid Tumors · study director
- Ph1NCT01113970 · Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast CancerAlaunos Therapeutics · terminated · Metastatic Breast Cancer · study director
- Ph2NCT00718484 · A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue SarcomaAlaunos Therapeutics · terminated · Soft Tissue Sarcoma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.